

Special Issue

Pharmacoepidemiology in Vaccine Safety and Efficacy

Message from the Guest Editors

The pharmacoepidemiology of vaccines provides near-real-time monitoring and scientific information for evidence-based decision-making. The field involves assessing the risks and benefits associated with vaccination programs, which includes monitoring adverse events following vaccination, evaluating vaccine effectiveness in preventing disease, and studying factors that influence vaccine uptake and effectiveness. This field provides evidence-based information to guide decision-making regarding vaccine development, recommendations, and implementation strategies. We are inviting original articles, review articles, brief communications, and case reports related to "Pharmacoepidemiology in Vaccine Safety and Efficacy" for this Special Issue.

Guest Editors

Dr. Chao-Min Cheng

Institute of Biomedical Engineering, National Tsing Hua University, Hsinchu City 300, Taiwan

Dr. Ching-Fen Shen

Department of Pediatrics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan

Deadline for manuscript submissions

closed (31 May 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/199819

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).